10-Q 1 novt-20240927.htm 10-Q 10-Q
false--12-310001076930Q3UnlimitedUnlimitedP1Yhttp://fasb.org/us-gaap/2024#PropertyPlantAndEquipmentNethttp://fasb.org/us-gaap/2024#PropertyPlantAndEquipmentNethttp://fasb.org/us-gaap/2024#OtherAccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2024#OtherAccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrentP0Yseven year4900001076930novt:FiscalYearTwentyTwentyFourMembersrt:MinimumMember2024-09-270001076930novt:TermLoanMembernovt:ThirdAmendedAndRestatedCreditAgreementMember2024-01-012024-09-270001076930us-gaap:CommonStockMember2022-12-310001076930us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-09-270001076930novt:RestOfEuropeMember2023-01-012023-09-290001076930novt:MotionSolutionsParentCorpMember2023-07-012023-09-290001076930novt:MotionSolutionsParentCorpMember2024-01-012024-09-270001076930us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-09-270001076930novt:SeveranceFacilityRelatedAndOtherChargesMembernovt:FiscalYearTwentyTwentyFourMember2024-06-292024-09-270001076930novt:FourthAmendmentRevolvingCreditFacilityMembernovt:ThirdAmendedAndRestatedCreditAgreementMember2021-10-050001076930novt:PrecisionMedicineAndManufacturingMember2023-12-310001076930us-gaap:FairValueInputsLevel3Member2023-12-310001076930us-gaap:OperatingSegmentsMembernovt:PrecisionMedicineAndManufacturingMember2024-06-292024-09-270001076930country:CN2023-01-012023-09-290001076930novt:RestOfEuropeMember2024-06-292024-09-270001076930us-gaap:RevolvingCreditFacilityMembernovt:ThirdAmendedAndRestatedCreditAgreementMember2024-01-012024-09-2700010769302024-10-290001076930us-gaap:AccumulatedTranslationAdjustmentMember2024-01-012024-09-270001076930us-gaap:AdditionalPaidInCapitalMember2024-06-292024-09-270001076930us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001076930country:US2023-01-012023-09-290001076930us-gaap:CostOfSalesMember2023-01-012023-09-290001076930novt:MedicalSolutionsMembernovt:FiscalYearTwentyTwentyFourMember2024-06-292024-09-270001076930us-gaap:RetainedEarningsMember2023-12-310001076930us-gaap:CommonStockMember2024-06-280001076930novt:ProfessionalAndConsultingFeesMember2024-01-012024-09-270001076930novt:RoboticsAndAutomationMemberus-gaap:OperatingSegmentsMember2023-01-012023-09-290001076930novt:EquityIncentivePlanTwentyTenMemberus-gaap:EmployeeStockOptionMember2024-02-012024-02-290001076930us-gaap:OperatingSegmentsMembernovt:PrecisionMedicineAndManufacturingMember2023-01-012023-09-290001076930us-gaap:OperatingExpenseMember2024-09-270001076930novt:EquityIncentivePlanTwentyTenMemberus-gaap:EmployeeStockOptionMember2024-09-270001076930us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-290001076930novt:RoboticsAndAutomationMember2023-12-310001076930us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-09-290001076930us-gaap:CorporateNonSegmentMember2024-01-012024-09-270001076930us-gaap:CommonStockMember2023-12-3100010769302023-09-290001076930country:DE2024-01-012024-09-270001076930novt:HybridPsusMembernovt:EquityIncentivePlanTwentyTenMembersrt:MinimumMember2024-01-012024-09-270001076930novt:TwoThousandTwentyCommonStockRepurchasePlanMember2024-01-012024-09-270001076930novt:FiscalYearTwentyTwentyTwoMember2023-01-012023-09-290001076930us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-09-270001076930novt:EmployeeRelatedMember2023-12-310001076930us-gaap:FairValueInputsLevel3Memberus-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001076930novt:MotionSolutionsParentCorpMemberus-gaap:CustomerRelationshipsMember2024-01-020001076930novt:HybridPsusMember2024-01-012024-09-270001076930us-gaap:ForeignExchangeForwardMember2023-01-012023-12-310001076930country:DE2023-01-012023-09-290001076930us-gaap:OtherRestructuringMember2023-12-310001076930us-gaap:TrademarksAndTradeNamesMember2024-09-270001076930us-gaap:AdditionalPaidInCapitalMember2024-06-280001076930novt:AttainmentBasedPsusMembernovt:EquityIncentivePlanTwentyTenMembersrt:MaximumMember2024-01-012024-09-270001076930novt:AdvancedIndustrialMember2023-07-012023-09-290001076930novt:RoboticsAndAutomationMemberus-gaap:OperatingSegmentsMember2024-06-292024-09-270001076930us-gaap:WarrantyObligationsMember2024-01-012024-09-270001076930us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-270001076930us-gaap:PerformanceSharesMembernovt:EquityIncentivePlanTwentyTenMember2024-09-270001076930novt:RoboticsAndAutomationMemberus-gaap:OperatingSegmentsMember2024-01-012024-09-270001076930us-gaap:CostOfSalesMember2024-01-012024-09-270001076930us-gaap:CanadaRevenueAgencyMembercountry:CA2024-01-012024-09-270001076930novt:MedicalSolutionsMemberus-gaap:OperatingSegmentsMember2024-01-012024-09-2700010769302024-06-292024-09-270001076930novt:MedicalSolutionsMemberus-gaap:OperatingSegmentsMember2024-06-292024-09-270001076930novt:FiscalYearTwentyTwentyMember2023-07-012023-09-290001076930us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-09-290001076930novt:EquityIncentivePlanTwentyTenMembernovt:MarketBasedPsusMembersrt:MaximumMember2024-01-012024-09-270001076930novt:AttainmentBasedPsusMembernovt:EquityIncentivePlanTwentyTenMembersrt:MinimumMember2024-01-012024-09-270001076930novt:EquityIncentivePlanTwentyTenMemberus-gaap:EmployeeStockOptionMember2023-12-3100010769302023-01-012023-12-310001076930country:US2024-06-292024-09-270001076930us-gaap:CanadaRevenueAgencyMembercountry:CA2023-07-012023-09-290001076930us-gaap:SellingGeneralAndAdministrativeExpensesMember2024-06-292024-09-270001076930us-gaap:CorporateNonSegmentMember2024-06-292024-09-270001076930novt:AttainmentBasedPsusAndHybridPsusMember2024-09-270001076930novt:RoboticsAndAutomationMembernovt:FiscalYearTwentyTwentyFourMember2024-01-012024-09-270001076930us-gaap:CorporateNonSegmentMember2023-01-012023-09-290001076930us-gaap:AdditionalPaidInCapitalMember2022-12-310001076930us-gaap:CommonStockMember2024-09-270001076930us-gaap:OtherRestructuringMember2024-01-012024-09-270001076930country:US2024-01-012024-09-270001076930us-gaap:CommonStockMember2024-06-292024-09-270001076930us-gaap:RestrictedStockUnitsRSUMembernovt:EquityIncentivePlanTwentyTenMember2023-12-3100010769302022-12-310001076930us-gaap:CommonStockMember2023-07-012023-09-290001076930novt:FiscalYearTwentyTwentyTwoMember2023-07-012023-09-290001076930us-gaap:RetainedEarningsMember2024-01-012024-09-270001076930novt:FourthAmendmentRevolvingCreditFacilityMember2021-10-050001076930us-gaap:CustomerRelationshipsMember2024-09-2700010769302021-05-310001076930us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001076930srt:MinimumMember2024-09-270001076930us-gaap:RevolvingCreditFacilityMembernovt:ThirdAmendedAndRestatedCreditAgreementMember2019-12-310001076930us-gaap:FairValueMeasurementsRecurringMember2024-09-270001076930country:CN2024-06-292024-09-270001076930us-gaap:CanadaRevenueAgencyMembercountry:CA2023-01-012023-09-290001076930us-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-09-290001076930us-gaap:DevelopedTechnologyRightsMembernovt:MotionSolutionsParentCorpMember2024-01-020001076930us-gaap:ForeignCurrencyGainLossMemberus-gaap:ForeignExchangeForwardMember2024-01-012024-09-270001076930us-gaap:CustomerRelationshipsMember2023-12-310001076930novt:TermLoanMembernovt:ThirdAmendedAndRestatedCreditAgreementMember2019-12-310001076930novt:OtherCountriesMember2023-07-012023-09-290001076930novt:TwoThousandTwentyCommonStockRepurchasePlanMember2020-02-290001076930novt:PrecisionMedicineAndManufacturingMember2024-09-270001076930novt:TwoThousandTwentyCommonStockRepurchasePlanMember2022-01-012022-12-310001076930us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-12-310001076930us-gaap:RevolvingCreditFacilityMember2023-12-310001076930novt:FiscalYearTwentyTwentyFourMember2024-09-270001076930us-gaap:OrderOrProductionBacklogMembernovt:MotionSolutionsParentCorpMember2024-01-022024-01-020001076930novt:MatthijsGlastraMember2024-06-292024-09-270001076930novt:FiscalYearTwentyTwentyFourMembernovt:UnallocatedCorporateAndSharedServicesMember2024-01-012024-09-270001076930novt:HybridPsusMembernovt:EquityIncentivePlanTwentyTenMembersrt:MaximumMember2024-01-012024-09-270001076930us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001076930novt:MotionSolutionsParentCorpMember2024-01-022024-01-020001076930novt:FiscalYearTwentyTwentyFourMember2024-01-012024-09-270001076930us-gaap:OperatingSegmentsMembernovt:PrecisionMedicineAndManufacturingMember2024-01-012024-09-270001076930novt:MedicalMember2024-01-012024-09-270001076930us-gaap:RestrictedStockUnitsRSUMembernovt:EquityIncentivePlanTwentyTenMembersrt:MinimumMember2024-01-012024-09-270001076930novt:OtherCountriesMember2023-01-012023-09-290001076930us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-290001076930us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-290001076930us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-270001076930us-gaap:ForeignCurrencyGainLossMemberus-gaap:ForeignExchangeForwardMember2024-06-292024-09-270001076930us-gaap:ResearchAndDevelopmentExpenseMember2024-06-292024-09-270001076930novt:TermLoanMember2023-12-310001076930novt:MedicalMember2023-07-012023-09-290001076930novt:EquityIncentivePlanTwentyTenMember2024-01-012024-09-270001076930us-gaap:FairValueInputsLevel2Memberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-270001076930us-gaap:CommonStockMember2024-01-012024-09-270001076930us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001076930us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-270001076930us-gaap:ForeignExchangeForwardMember2024-01-012024-09-270001076930country:CN2023-07-012023-09-290001076930novt:FirstAmendmentRevolvingCreditFacilityMember2020-03-270001076930us-gaap:PerformanceSharesMembernovt:EquityIncentivePlanTwentyTenMember2023-12-310001076930us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-01-012024-09-270001076930us-gaap:CostOfSalesMember2024-09-270001076930us-gaap:OrderOrProductionBacklogMembernovt:MotionSolutionsParentCorpMember2024-01-020001076930country:CN2024-01-012024-09-270001076930novt:RestrictedStockUnitsAndDeferredStockUnitsMembersrt:DirectorMembernovt:EquityIncentivePlanTwentyTenMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2024-01-012024-09-270001076930us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-2800010769302024-01-012024-09-270001076930novt:MotionSolutionsParentCorpMember2024-03-302024-06-280001076930novt:MedicalSolutionsMemberus-gaap:OperatingSegmentsMember2023-01-012023-09-290001076930us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001076930us-gaap:CommonStockMember2023-01-012023-09-2900010769302023-12-310001076930us-gaap:AdditionalPaidInCapitalMember2023-09-290001076930us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300001076930srt:DirectorMembernovt:RestrictedStockUnitsAndDeferredStockUnitsMembernovt:EquityIncentivePlanTwentyTenMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-09-290001076930us-gaap:OtherRestructuringMember2024-09-270001076930novt:MedicalSolutionsMembernovt:FiscalYearTwentyTwentyFourMember2024-01-012024-09-270001076930us-gaap:RevolvingCreditFacilityMembernovt:ThirdAmendedAndRestatedCreditAgreementMember2019-12-302019-12-310001076930us-gaap:FairValueMeasurementsRecurringMembernovt:AccruedExpensesAndOtherCurrentLiabilitiesMember2024-09-270001076930us-gaap:AdditionalPaidInCapitalMember2023-01-012023-09-290001076930us-gaap:ForeignCurrencyGainLossMemberus-gaap:ForeignExchangeForwardMember2023-07-012023-09-290001076930us-gaap:AdditionalPaidInCapitalMember2024-01-012024-09-2700010769302024-03-302024-06-280001076930novt:MedicalSolutionsMember2024-09-2700010769302024-06-280001076930us-gaap:RestrictedStockUnitsRSUMembernovt:EquityIncentivePlanTwentyTenMember2024-01-012024-09-270001076930novt:TermLoanMembernovt:ThirdAmendedAndRestatedCreditAgreementMember2020-03-012020-03-310001076930us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-09-290001076930srt:MinimumMemberus-gaap:WarrantyObligationsMember2024-01-012024-09-270001076930novt:OtherCountriesMember2024-01-012024-09-270001076930novt:FiscalYearTwentyTwentyFourMembersrt:MaximumMember2024-09-270001076930us-gaap:RestrictedStockUnitsRSUMembernovt:EquityIncentivePlanTwentyTenMember2024-09-270001076930us-gaap:RetainedEarningsMember2023-07-012023-09-290001076930us-gaap:RetainedEarningsMember2023-01-012023-09-290001076930novt:MedicalSolutionsMemberus-gaap:OperatingSegmentsMember2023-07-012023-09-290001076930us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMembernovt:AccruedExpensesAndOtherCurrentLiabilitiesMember2024-09-270001076930us-gaap:RestrictedStockUnitsRSUMembernovt:EquityIncentivePlanTwentyTenMembersrt:MaximumMember2024-01-012024-09-270001076930us-gaap:AccumulatedTranslationAdjustmentMember2024-09-270001076930novt:AdvancedIndustrialMember2024-06-292024-09-270001076930us-gaap:AdditionalPaidInCapitalMember2024-09-270001076930us-gaap:TechnologyBasedIntangibleAssetsMember2024-09-270001076930us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-270001076930novt:RestOfAsiaPacificMember2024-06-292024-09-270001076930us-gaap:AdditionalPaidInCapitalMember2023-06-3000010769302023-06-300001076930novt:AdvancedIndustrialMember2023-01-012023-09-290001076930novt:RestOfEuropeMember2023-07-012023-09-290001076930novt:MedicalMember2023-01-012023-09-290001076930srt:MaximumMemberus-gaap:LandMember2024-01-012024-09-270001076930us-gaap:FairValueMeasurementsRecurringMember2023-12-310001076930us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-292024-09-270001076930novt:AttainmentBasedPsusAndHybridPsusMember2023-09-290001076930us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-270001076930us-gaap:FairValueInputsLevel3Member2024-01-012024-09-270001076930us-gaap:SellingGeneralAndAdministrativeExpensesMember2024-01-012024-09-270001076930us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001076930us-gaap:CommonStockMember2023-09-290001076930us-gaap:FacilityClosingMember2024-09-270001076930novt:ProfessionalAndConsultingFeesMember2023-01-012023-09-290001076930us-gaap:TrademarksAndTradeNamesMember2023-12-310001076930us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001076930us-gaap:CostOfSalesMember2023-07-012023-09-290001076930novt:RoboticsAndAutomationMember2024-09-270001076930novt:RestOfAsiaPacificMember2023-07-012023-09-290001076930novt:ThirdAmendedAndRestatedCreditAgreementMember2019-12-302019-12-310001076930novt:ProfessionalAndConsultingFeesMember2023-07-012023-09-290001076930us-gaap:OrderOrProductionBacklogMember2024-09-270001076930us-gaap:FacilityClosingMember2023-12-310001076930country:DE2023-07-012023-09-290001076930novt:MatthijsGlastraMember2024-09-270001076930srt:MaximumMembernovt:ProfessionalServicesMember2024-01-012024-09-270001076930novt:HybridPsusMember2024-09-270001076930novt:ProfessionalAndConsultingFeesMember2024-06-292024-09-270001076930novt:FiscalYearTwentyTwentyFourMember2024-06-292024-09-270001076930country:DE2024-06-292024-09-270001076930us-gaap:PerformanceSharesMembernovt:EquityIncentivePlanTwentyTenMember2024-01-012024-09-270001076930novt:MedicalMember2024-06-292024-09-270001076930novt:FifthAmendmentRevolvingCreditFacilityMembernovt:ThirdAmendedAndRestatedCreditAgreementMember2022-03-100001076930us-gaap:DevelopedTechnologyRightsMembernovt:MotionSolutionsParentCorpMember2024-01-022024-01-020001076930novt:RestOfEuropeMember2024-01-012024-09-270001076930novt:FiscalYearTwentyTwentyFourMembernovt:PrecisionMedicineAndManufacturingMember2024-01-012024-09-270001076930us-gaap:CanadaRevenueAgencyMembercountry:CA2024-06-292024-09-270001076930us-gaap:AdditionalPaidInCapitalMember2023-12-310001076930us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-07-012023-09-290001076930us-gaap:AccumulatedTranslationAdjustmentMember2023-12-310001076930novt:EmployeeRelatedMember2024-01-012024-09-270001076930novt:EquityIncentivePlanTwentyTenMembersrt:MinimumMembernovt:MarketBasedPsusMember2024-01-012024-09-270001076930us-gaap:RetainedEarningsMember2022-12-310001076930novt:TermLoanAndRevolvingCreditFacilityMember2024-09-270001076930novt:RoboticsAndAutomationMembernovt:FiscalYearTwentyTwentyFourMember2024-06-292024-09-270001076930us-gaap:CommonStockMember2023-06-300001076930novt:FiscalYearTwentyTwentyFourMembernovt:PrecisionMedicineAndManufacturingMember2024-06-292024-09-270001076930us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMembernovt:AccruedExpensesAndOtherCurrentLiabilitiesMember2024-09-270001076930novt:RestOfAsiaPacificMember2024-01-012024-09-270001076930novt:RoboticsAndAutomationMemberus-gaap:OperatingSegmentsMember2023-07-012023-09-2900010769302021-05-012021-05-310001076930novt:TermLoanMember2024-09-270001076930novt:MotionSolutionsParentCorpMember2024-06-292024-09-270001076930us-gaap:CorporateNonSegmentMember2023-07-012023-09-290001076930us-gaap:FacilityClosingMember2024-01-012024-09-270001076930us-gaap:RetainedEarningsMember2024-06-292024-09-270001076930us-gaap:ForeignExchangeForwardMember2023-12-310001076930novt:MotionSolutionsParentCorpMember2023-01-012023-09-290001076930novt:MedicalSolutionsMember2023-12-310001076930novt:ThirdAmendedAndRestatedCreditAgreementMember2019-12-310001076930us-gaap:RetainedEarningsMember2024-09-270001076930us-gaap:FairValueMeasurementsRecurringMembernovt:AccruedExpensesAndOtherCurrentLiabilitiesMember2023-12-310001076930novt:MotionSolutionsParentCorpMemberus-gaap:CustomerRelationshipsMember2024-01-022024-01-0200010769302023-07-012023-09-290001076930us-gaap:ForeignExchangeForwardMember2024-09-270001076930country:US2023-07-012023-09-290001076930us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMembernovt:AccruedExpensesAndOtherCurrentLiabilitiesMember2023-12-310001076930novt:EquityIncentivePlanTwentyTenMemberus-gaap:EmployeeStockOptionMember2024-01-012024-09-270001076930novt:SeveranceFacilityRelatedAndOtherChargesMembernovt:FiscalYearTwentyTwentyFourMember2024-01-012024-09-270001076930novt:EmployeeRelatedMember2024-09-270001076930novt:TermLoanMembernovt:ThirdAmendedAndRestatedCreditAgreementMember2019-12-302019-12-310001076930novt:TwoThousandTwentyCommonStockRepurchasePlanMember2024-09-270001076930us-gaap:OperatingSegmentsMembernovt:PrecisionMedicineAndManufacturingMember2023-07-012023-09-290001076930us-gaap:RevolvingCreditFacilityMember2024-09-270001076930us-gaap:FairValueInputsLevel3Member2024-09-270001076930srt:MinimumMember2024-01-012024-09-2700010769302023-01-012023-09-290001076930us-gaap:RetainedEarningsMember2023-09-290001076930us-gaap:FairValueInputsLevel3Memberus-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-270001076930srt:MaximumMember2024-09-270001076930us-gaap:ForeignCurrencyGainLossMemberus-gaap:ForeignExchangeForwardMember2023-01-012023-09-290001076930novt:FiscalYearTwentyTwentyMember2023-01-012023-09-290001076930novt:OtherCountriesMember2024-06-292024-09-270001076930us-gaap:RetainedEarningsMember2024-06-280001076930us-gaap:RetainedEarningsMember2023-06-300001076930us-gaap:WarrantyObligationsMembersrt:MaximumMember2024-01-012024-09-270001076930srt:MaximumMember2024-01-012024-09-270001076930us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMembernovt:AccruedExpensesAndOtherCurrentLiabilitiesMember2023-12-3100010769302024-09-270001076930novt:MotionSolutionsParentCorpMember2024-01-0200010769302024-01-010001076930novt:AdvancedIndustrialMember2024-01-012024-09-270001076930us-gaap:TechnologyBasedIntangibleAssetsMember2023-12-310001076930us-gaap:CostOfSalesMember2024-06-292024-09-270001076930us-gaap:FairValueInputsLevel2Memberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001076930novt:RestOfAsiaPacificMember2023-01-012023-09-290001076930us-gaap:EmployeeStockOptionMember2024-01-012024-09-270001076930novt:TermLoanAndRevolvingCreditFacilityMember2023-12-310001076930novt:FiscalYearTwentyTwentyFourMembernovt:UnallocatedCorporateAndSharedServicesMember2024-06-292024-09-27iso4217:EURiso4217:USDxbrli:sharesxbrli:purenovt:EndMarketnovt:Segmentxbrli:sharesiso4217:USD

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 27, 2024

Or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from __________ to __________

Commission File No.: 001-35083

NOVANTA INC.

(Exact name of registrant as specified in its charter)

New Brunswick, Canada

98-0110412

(State or other jurisdiction of incorporation or organization)

(I.R.S. Employer Identification No.)

 

 

 

125 Middlesex Turnpike, Bedford, Massachusetts, USA

01730

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (781) 266-5700

N/A

(Former name, former address and former fiscal year, if changed since last report)

 

 

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

Common shares, no par value

 

NOVT

 

The Nasdaq Global Select Market

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

 

Large accelerated filer

Accelerated filer

 

 

Non-accelerated filer

Smaller reporting company

 

 

 

 

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

As of October 29, 2024, there were 35,921,328 of the Registrant’s common shares, no par value, issued and outstanding.

 

 


 

NOVANTA INC.

TABLE OF CONTENTS

Item No.

 

Page
No.

 

 

PART I — FINANCIAL INFORMATION

1

 

 

 

ITEM 1.

FINANCIAL STATEMENTS

1

 

 

 

CONSOLIDATED BALANCE SHEETS (unaudited)

1

 

 

 

CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)

2

 

 

 

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (unaudited)

3

 

 

 

 

 

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (unaudited)

 

4

 

 

 

 

 

CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)

5

 

 

 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited)

6

 

 

 

ITEM 2.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

27

 

 

 

ITEM 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

39

 

 

 

ITEM 4.

CONTROLS AND PROCEDURES

39

 

 

PART II — OTHER INFORMATION

40

 

 

 

ITEM 1.

LEGAL PROCEEDINGS

40

 

 

 

ITEM 1A.

RISK FACTORS

40

 

 

 

ITEM 2.

UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

40

 

 

 

ITEM 3.

DEFAULTS UPON SENIOR SECURITIES

40

 

 

 

ITEM 4.

MINE SAFETY DISCLOSURES

40

 

 

 

ITEM 5.

OTHER INFORMATION

40

 

 

 

ITEM 6.

EXHIBITS

41

 

 

SIGNATURES

42

 

 

 

 


 

 

PART I—FINANCIAL INFORMATION

Item 1. Financial Statements

NOVANTA INC.

CONSOLIDATED BALANCE SHEETS

(In thousands of U.S. dollars or shares)

(Unaudited)

 

September 27,

 

 

December 31,

 

 

2024

 

 

2023

 

ASSETS

 

 

 

 

 

Current assets

 

 

 

 

 

Cash and cash equivalents

$

92,690

 

 

$

105,051

 

Accounts receivable, net of allowance of $630 and $571, respectively

 

164,502

 

 

 

139,410

 

Inventories

 

154,021

 

 

 

149,371

 

Prepaid income taxes and income taxes receivable

 

12,844

 

 

 

8,105

 

Prepaid expenses and other current assets

 

12,877

 

 

 

13,360

 

Total current assets

 

436,934

 

 

 

415,297

 

Property, plant and equipment, net

 

119,596

 

 

 

109,449

 

Operating lease assets

 

44,645

 

 

 

38,302

 

Deferred tax assets

 

19,239

 

 

 

27,862

 

Other assets

 

5,927

 

 

 

5,617

 

Intangible assets, net

 

198,394

 

 

 

145,022

 

Goodwill

 

594,088

 

 

 

484,507

 

Total assets

$

1,418,823

 

 

$

1,226,056

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

 

 

Current liabilities

 

 

 

 

 

Current portion of long-term debt

$

5,016

 

 

$

4,968

 

Accounts payable

 

68,720

 

 

 

57,195

 

Income taxes payable

 

15,414

 

 

 

7,767

 

Current portion of operating lease liabilities

 

9,981

 

 

 

8,189

 

Accrued expenses and other current liabilities

 

57,469

 

 

 

61,056

 

Total current liabilities

 

156,600

 

 

 

139,175

 

Long-term debt

 

452,502

 

 

 

349,404

 

Operating lease liabilities

 

42,672

 

 

 

37,345

 

Deferred tax liabilities

 

14,324

 

 

 

16,305

 

Income taxes payable

 

5,340

 

 

 

4,435

 

Other liabilities

 

5,190

 

 

 

5,932

 

Total liabilities

 

676,628

 

 

 

552,596

 

Commitments and contingencies (Note 15)

 

 

 

 

 

Stockholders’ equity:

 

 

 

 

 

Preferred shares, no par value; Authorized shares: 7,000;
   
No shares issued and outstanding

 

 

 

 

 

Common shares, no par value; Authorized shares: unlimited;
   Issued and outstanding:
35,916 and 35,814, respectively

 

423,856

 

 

 

423,856

 

Additional paid-in capital

 

79,928

 

 

 

70,180

 

Retained earnings

 

251,085

 

 

 

203,462

 

Accumulated other comprehensive loss

 

(12,674

)

 

 

(24,038

)

Total stockholders' equity

 

742,195

 

 

 

673,460

 

Total liabilities and stockholders’ equity

$

1,418,823

 

 

$

1,226,056

 

 

The accompanying notes are an integral part of these consolidated financial statements.

1


 

NOVANTA INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands of U.S. dollars or shares, except per share amounts)

(Unaudited)

 

Three Months Ended

 

 

Nine Months Ended

 

 

September 27,

 

 

September 29,

 

 

September 27,

 

 

September 29,

 

 

2024

 

 

2023

 

 

2024

 

 

2023

 

Revenue

$

244,405

 

 

$

221,503

 

 

$

711,185

 

 

$

670,093

 

Cost of revenue

 

135,190

 

 

 

119,912

 

 

 

397,865

 

 

 

366,751

 

Gross profit

 

109,215

 

 

 

101,591

 

 

 

313,320

 

 

 

303,342

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

Research and development and engineering

 

23,253

 

 

 

22,022

 

 

 

70,230

 

 

 

68,230

 

Selling, general and administrative

 

44,319

 

 

 

39,648

 

 

 

132,642

 

 

 

122,758

 

Amortization of purchased intangible assets

 

6,589

 

 

 

5,131

 

 

 

19,246

 

 

 

15,344

 

Restructuring, acquisition, and related costs

 

2,499

 

 

 

4,481

 

 

 

7,325

 

 

 

8,191

 

Total operating expenses

 

76,660

 

 

 

71,282

 

 

 

229,443

 

 

 

214,523

 

Operating income

 

32,555

 

 

 

30,309

 

 

 

83,877

 

 

 

88,819

 

Interest income (expense), net

 

(8,079

)

 

 

(6,756

)

 

 

(24,599

)

 

 

(19,898

)

Foreign exchange transaction gains (losses), net

 

(202

)

 

 

(370

)

 

 

(787

)

 

 

(373

)

Other income (expense), net

 

(49

)

 

 

(189

)

 

 

(220

)

 

 

(546

)

Income before income taxes

 

24,225

 

 

 

22,994

 

 

 

58,271

 

 

 

68,002

 

Income tax provision

 

5,033

 

 

 

1,771

 

 

 

10,648

 

 

 

7,635

 

Net income

$

19,192

 

 

$

21,223

 

 

$

47,623

 

 

$

60,367

 

 

 

 

 

 

 

 

 

 

 

 

 

Earnings per common share (Note 5):

 

 

 

 

 

 

 

 

 

 

 

Basic

$

0.53

 

 

$

0.59

 

 

$

1.33

 

 

$

1.68

 

Diluted

$

0.53

 

 

$

0.59

 

 

$

1.32

 

 

$

1.68

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average common shares outstanding—basic

 

35,959

 

 

 

35,856

 

 

 

35,940

 

 

 

35,839

 

Weighted average common shares outstanding—diluted

 

36,129

 

 

 

36,041

 

 

 

36,116

 

 

 

36,024

 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

2


 

NOVANTA INC.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

(In thousands of U.S. dollars)

(Unaudited)

 

Three Months Ended

 

 

Nine Months Ended

 

 

September 27,

 

 

September 29,

 

 

September 27,

 

 

September 29,

 

 

2024

 

 

2023

 

 

2024

 

 

2023

 

Net income

$

19,192

 

 

$

21,223

 

 

$

47,623

 

 

$

60,367

 

Other comprehensive income (loss):

 

 

 

 

 

 

 

 

 

 

 

Foreign currency translation adjustments, net of tax (1)

 

14,869

 

 

 

(8,786

)

 

 

11,053

 

 

 

(1,980

)

Pension liability adjustments, net of tax (2)

 

(159

)

 

 

515

 

 

 

311

 

 

 

676

 

Total other comprehensive income (loss)

 

14,710

 

 

 

(8,271

)

 

 

11,364

 

 

 

(1,304

)

Total consolidated comprehensive income

$

33,902

 

 

$

12,952

 

 

$

58,987

 

 

$

59,063

 

 

(1)
The tax effect on this component of comprehensive income (loss) was nominal for all periods presented.
(2)
The tax effect on this component of comprehensive income (loss) was nominal for all periods presented. See Note 4 to the Consolidated Financial Statements for the total amount of pension liability adjustments reclassified out of accumulated other comprehensive income (loss).

The accompanying notes are an integral part of these consolidated financial statements.

 

3


 

NOVANTA INC.

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(In thousands of U.S. dollars or shares)

(Unaudited)

 

 

Common Shares

 

 

Additional Paid-In

 

 

Retained

 

 

Accumulated Other

 

 

 

 

 

# of Shares

 

 

Amount

 

 

Capital

 

 

Earnings

 

 

Comprehensive Loss

 

 

Total

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended September 27, 2024

 

Balance at June 28, 2024

 

35,895

 

 

$

423,856

 

 

$

73,627

 

 

$

231,893

 

 

$

(27,384

)

 

$

701,992

 

Net income

 

 

 

 

 

 

 

 

 

 

19,192

 

 

 

 

 

 

19,192

 

Common shares issued under stock plans

 

23

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Common shares withheld for taxes on vested stock awards

 

(2

)

 

 

 

 

 

(63

)

 

 

 

 

 

 

 

 

(63

)

Share-based compensation

 

 

 

 

 

 

 

6,364

 

 

 

 

 

 

 

 

 

6,364

 

Other comprehensive income (loss), net of tax

 

 

 

 

 

 

 

 

 

 

 

 

 

14,710

 

 

 

14,710

 

Balance at September 27, 2024

 

35,916

 

 

$

423,856

 

 

$

79,928

 

 

$

251,085

 

 

$

(12,674

)

 

$

742,195

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Nine Months Ended September 27, 2024

 

Balance at December 31, 2023

 

35,814

 

 

$

423,856

 

 

$

70,180

 

 

$

203,462

 

 

$

(24,038

)

 

$

673,460

 

Net income

 

 

 

 

 

 

 

 

 

 

47,623

 

 

 

 

 

 

47,623

 

Common shares issued under stock plans

 

159

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Common shares withheld for taxes on vested stock awards

 

(57

)

 

 

 

 

 

(8,924

)

 

 

 

 

 

 

 

 

(8,924

)

Share-based compensation

 

 

 

 

 

 

 

18,672

 

 

 

 

 

 

 

 

 

18,672

 

Other comprehensive income (loss), net of tax

 

 

 

 

 

 

 

 

 

 

 

 

 

11,364

 

 

 

11,364

 

Balance at September 27, 2024

 

35,916

 

 

$

423,856

 

 

$

79,928

 

 

$

251,085

 

 

$

(12,674

)

 

$

742,195

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended September 29, 2023

 

Balance at June 30, 2023

 

35,808

 

 

$

423,856

 

 

$

57,488

 

 

$

169,728

 

 

$

(25,042

)

 

$

626,030

 

Net income

 

 

 

 

 

 

 

 

 

 

21,223

 

 

 

 

 

 

21,223

 

Common shares issued under stock plans

 

3

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Common shares withheld for taxes on vested stock awards

 

(1

)

 

 

 

 

 

(163

)

 

 

 

 

 

 

 

 

(163

)

Share-based compensation

 

 

 

 

 

 

 

6,037

 

 

 

 

 

 

 

 

 

6,037

 

Other comprehensive income (loss), net of tax

 

 

 

 

 

 

 

 

 

 

 

 

 

(8,271

)

 

 

(8,271

)

Balance at September 29, 2023

 

35,810

 

 

$

423,856

 

 

$

63,362

 

 

$

190,951

 

 

$

(33,313

)

 

$

644,856

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Nine Months Ended September 29, 2023

 

Balance at December 31, 2022

 

35,711

 

 

$

423,856

 

 

$

55,155

 

 

$

130,584

 

 

$

(32,009

)

 

$

577,586

 

Net income

 

 

 

 

 

 

 

 

 

 

60,367

 

 

 

 

 

 

60,367

 

Common shares issued under stock plans

 

167

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Common shares withheld for taxes on vested stock awards

 

(68

)

 

 

 

 

 

(10,171

)

 

 

 

 

 

 

 

 

(10,171

)

Share-based compensation

 

 

 

 

 

 

 

18,378

 

 

 

 

 

 

 

 

 

18,378

 

Other comprehensive income (loss), net of tax

 

 

 

 

 

 

 

 

 

 

 

 

 

(1,304

)

 

 

(1,304

)

Balance at September 29, 2023

 

35,810

 

 

$

423,856

 

 

$

63,362

 

 

$

190,951

 

 

$

(33,313

)

 

$

644,856

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

The accompanying notes are an integral part of these consolidated financial statements.

4


 

NOVANTA INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands of U.S. dollars)

(Unaudited)

 

Nine Months Ended

 

 

September 27,

 

 

September 29,

 

 

2024

 

 

2023

 

Cash flows from operating activities:

 

 

 

 

 

Net income

$

47,623

 

 

$

60,367

 

Adjustments to reconcile net income to
   net cash provided by operating activities:

 

 

 

 

 

Depreciation and amortization

 

41,200

 

 

 

35,065

 

Provision for inventory excess and obsolescence

 

7,325

 

 

 

6,563

 

Impairment of assets

 

 

 

 

1,421

 

Share-based compensation

 

18,672

 

 

 

18,378

 

Deferred income taxes

 

(11,908

)

 

 

(12,328

)

Inventory acquisition fair value adjustments

 

2,777

 

 

 

 

Other

 

1,273

 

 

 

1,289

 

Changes in assets and liabilities which (used)/provided cash, excluding
   effects from business acquisitions:

 

 

 

 

 

Accounts receivable

 

(16,087

)

 

 

(6,371

)

Inventories

 

416

 

 

 

5,619

 

Prepaid income taxes, income taxes receivable, prepaid expenses
     and other current assets

 

(2,378

)

 

 

(3,444

)

Accounts payable, income taxes payable, accrued expenses
     and other current liabilities

 

7,506

 

 

 

(24,759

)

Other non-current assets and liabilities

 

531

 

 

 

(717

)

Net cash provided by operating activities

 

96,950

 

 

 

81,083

 

Cash flows from investing activities:

 

 

 

 

 

Cash paid for business acquisitions, net of working capital adjustments

 

(191,200

)

 

 

 

Purchases of property, plant and equipment

 

(14,913

)

 

 

(13,741

)

Net cash used in investing activities

 

(206,113

)

 

 

(13,741

)

Cash flows from financing activities:

 

 

 

 

 

Borrowings under revolving credit facilities

 

198,000

 

 

 

 

Repayments under term loan and revolving credit facilities

 

(95,983

)

 

 

(82,047

)

Payments of withholding taxes from share-based awards

 

(8,924

)

 

 

(10,171

)

Other financing activities

 

(534

)

 

 

(565

)

Net cash provided by (used in) financing activities

 

92,559

 

 

 

(92,783

)

Effect of exchange rates on cash and cash equivalents

 

4,243

 

 

 

1,297

 

Decrease in cash and cash equivalents

 

(12,361

)

 

 

(24,144

)

Cash and cash equivalents, beginning of the period

 

105,051

 

 

 

100,105

 

Cash and cash equivalents, end of the period

$

92,690

 

 

$

75,961

 

Supplemental disclosure of cash flow information:

 

 

 

 

 

Cash paid for interest

$

25,376

 

 

$

19,290

 

Cash paid for income taxes

$

18,807

 

 

$

28,684

 

Income tax refunds received

$

1,069

 

 

$

275

 

 

The accompanying notes are an integral part of these consolidated financial statements.

5


 

NOVANTA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AS OF SEPTEMBER 27, 2024

(Unaudited)

1. Basis of Presentation

Novanta Inc. (collectively with its subsidiaries, referred to as “Novanta”, the “Company”, “we”, “us”, “our”) is a leading global supplier of core technology solutions that give medical and advanced industrial original equipment manufacturers (“OEMs”) a competitive advantage. Novanta combines deep proprietary technology expertise and competencies in precision medicine and manufacturing, medical solutions and robotics and automation with a proven ability to solve complex technical challenges. This enables Novanta to engineer core components and sub-systems that deliver extreme precision and performance, tailored to the customers’ demanding applications.

The accompanying unaudited interim consolidated financial statements have been prepared by the Company in United States (“U.S.”) dollars and pursuant to the rules and regulations of the United States Securities and Exchange Commission (“SEC”), the instructions to Form 10-Q and the provisions of Regulation S-X pertaining to interim financial statements. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the U.S. have been condensed or omitted. The interim consolidated financial statements and notes included in this report should be read in conjunction with the consolidated financial statements and notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023. In the opinion of management, these interim consolidated financial statements include all adjustments and accruals of a normal and recurring nature necessary to fairly state the results of the interim periods presented. The results for interim periods are not necessarily indicative of results to be expected for the full year or for any future periods.

The Company’s unaudited interim consolidated financial statements are prepared for each quarterly period ending on the Friday closest to the end of the calendar quarter, with the exception of the fourth quarter which always ends on December 31.

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of revenue and expenses during the reporting periods. Estimates and assumptions are reviewed on an on-going basis and the effects of revisions are reflected in the period in which such revisions are deemed to be necessary. The Company evaluates its estimates based on historical experience, current conditions, and various other assumptions that it believes are reasonable under the circumstances. Actual results could differ significantly from these estimates.

6


NOVANTA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AS OF SEPTEMBER 27, 2024

(Unaudited)

 

Recent Accounting Pronouncements

The following table provides a brief description of recent Accounting Standards Updates (“ASU”) issued by the Financial Accounting Standards Board (“FASB”):

Standard

 

Description

 

Effective Date

 

Effect on the Financial Statements or Other Significant Matters

In November 2023, the FASB issued ASU 2023-07, "Segment Reporting (Topic 280) -Improvements to Reportable Segment Disclosures."

 

ASU 2023-07 clarifies or improves financial reporting by requiring disclosure of incremental segment information. The amendments require disclosure, on an annual and interim basis for all public entities, of significant segment expenses included in segment profit or loss, an amount and description of "other segment items" included in segment profit or loss, and an explanation of how reported segment profit or loss is assessed and allocated.

 

The amendments in ASU 2023-07 are effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted.

 

The Company is currently evaluating the impact of ASU 2023-07 on its consolidated financial statement disclosures.

In December 2023, the FASB issued ASU 2023-09, "Income Taxes (Topic 740) -Improvements to Income Tax Disclosures."

 

ASU 2023-09 provides more transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid.

 

The amendments in ASU 2023-09 are effective for annual periods beginning after December 15, 2024. Early adoption is permitted.

 

The Company is currently evaluating the impact of ASU 2023-09 on its consolidated financial statement disclosures.

 

2. Revenue

The Company accounts for its revenue transactions in accordance with Accounting Standards Codification (“ASC”) Topic 606, “Revenue from Contracts with Customers,” which requires entities to recognize revenue in a way that depicts the transfer of control over goods or services to customers at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.

The Company recognizes revenue when control of promised goods or services is transferred to the customer. The transfer of control generally occurs upon shipment when title and risk of loss pass to the customer. The vast majority of the Company’s revenue is generated from the sale of distinct products. Revenue is measured as the amount of consideration the Company expects to receive in exchange for such products, which is generally at contractually stated prices. Sales taxes and value added taxes collected concurrently with revenue generating activities are excluded from revenue.

Performance Obligations

Substantially all of the Company’s revenue is recognized at a point in time, upon shipment, rather than over time.

At the request of its customers, the Company may perform professional services, generally for the maintenance and repair of products previously sold to those customers and for engineering services. Professional services are typically short in duration and aggregate to less than 3% of the Company’s consolidated revenue. Revenue is typically recognized at a point in time when control transfers to the customer upon completion of professional services. These services generally involve a single distinct performance obligation. The consideration expected to be received in exchange for such services is normally the contractually stated amount.

The Company occasionally sells separately priced non-standard/extended warranty services or preventative maintenance plans with the sale of products. The transfer of control over the service plans is over time. The Company recognizes the related revenue

7


NOVANTA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AS OF SEPTEMBER 27, 2024

(Unaudited)

 

ratably over the terms of the service plans. The transaction price of a contract is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are generally determined based on the prices charged to customers or using the expected cost plus a margin.

Shipping & Handling Costs

The Company accounts for shipping and handling activities that occur after the transfer of control over the related goods as fulfillment activities rather than performance obligations. Shipping and handling fees charged to customers are recognized as revenue and the related costs are recorded in cost of revenue at the time of transfer of control.

Warranties

The standard warranty periods for the Company’s products are typically 12 months to 36 months. The Company recognizes estimated liabilities associated with standard warranty periods for its products in accordance with the provisions of ASC 450, “Contingencies,” as the Company has the ability to ascertain the likelihood of the liabilities and can reasonably estimate the amount of the liabilities. A provision for the estimated cost related to standard warranties is recorded as cost of revenue at the time revenue is recognized. The Company’s estimate of the costs to service the warranty obligations is based on historical experience and expectations of future conditions. To the extent that the Company’s experience in warranty claims or costs associated with servicing those claims differ from the original estimates, revisions to the estimated warranty liabilities are recorded at that time, with offsetting adjustments to cost of revenue.

Practical Expedients and Exemptions

The Company expenses incremental direct costs of obtaining a contract when incurred because the expected amortization period is typically one year or less. These costs are recorded within selling, general and administrative expenses in the consolidated statement of operations.

The Company does not adjust the promised amount of consideration for the effects of a financing component because the transfer of a promised good to a customer and the customer’s payment for that good are typically one year or less. The Company does not disclose the value of the remaining performance obligation for contracts with an original expected length of one year or less.

Contract Liabilities

Contract liabilities consist of deferred revenue and advance payments from customers, including amounts that are refundable. These contract liabilities are classified as either current or long-term liabilities in the consolidated balance sheet based on the timing of when the Company expects to recognize the related revenue. As of September 27, 2024 and December 31, 2023, contract liabilities were $8.3 million and $5.8 million, respectively, and are included in accrued expenses and other current liabilities and other liabilities in the accompanying consolidated balance sheets. The increase in the contract liability balance during the nine months ended September 27, 2024 is primarily due to cash payments received in advance of satisfying performance obligations, partially offset by $4.5 million of revenue recognized during the period that was included in the contract liability balance as of December 31, 2023.

Disaggregated Revenue

See Note 16 for the Company’s disaggregation of revenue by segment, geography and end market.

3. Business Combinations

On January 2, 2024, the Company completed the acquisition of Motion Solutions Parent Corp. (“Motion Solutions”), an Irvine, California-based provider of highly engineered integrated solutions, specializing in proprietary precision motion and advanced motion control solutions, for a total purchase price of $192.0 million in cash, net of working capital adjustments. The acquisition was financed with borrowings under the Company’s revolving credit facility. The addition of Motion Solutions enhances the Company’s product portfolio and further expands its presence in attractive medical and precision medicine spaces. Motion Solutions is included in the Medical Solutions reportable segment.

8


NOVANTA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AS OF SEPTEMBER 27, 2024

(Unaudited)

 

Allocation of Purchase Price

The acquisition of Motion Solutions has been accounted for as a business combination. The purchase price is allocated based upon a valuation of the fair values of assets acquired and liabilities assumed. Assets acquired and liabilities assumed have been recorded at their estimated fair values as of the acquisition date. The excess of the purchase price over the fair values of the acquired tangible assets, identifiable intangible assets and assumed liabilities was recorded as goodwill. The fair values of identifiable intangible assets were based on valuations using an income approach, specifically the multi-period excess earnings method for customer relationships and the relief-from-royalty method for developed technologies. The process for estimating the fair values of identifiable intangible assets requires the use of significant estimates and assumptions, including revenue growth rates, customer attrition rates, royalty rates, discount rates, technology obsolescence curves, and EBITDA margins. The Company’s estimates and assumptions in determining the estimated fair value of certain assets and liabilities are subject to change within the measurement period (up to one year from the acquisition date) as a result of additional information to be obtained with regard to facts and circumstances that existed as of the acquisition date.

Based upon the Company’s preliminary valuation, the purchase price for Motion Solutions was allocated as follows (in thousands):

 

Purchase Price

 

 

Allocation

 

Cash

$

776

 

Accounts receivable

 

8,515

 

Inventory

 

14,032

 

Property, plant and equipment

 

3,126

 

Operating lease assets

 

8,076

 

Intangible assets

 

83,000

 

Goodwill

 

106,569

 

Other assets

 

1,002

 

Total assets acquired

 

225,096

 

Accounts payable

 

5,305

 

Operating lease liabilities

 

8,514

 

Deferred tax liabilities

 

18,171

 

Other liabilities

 

1,130

 

Total liabilities assumed

 

33,120

 

Total assets acquired, net of liabilities assumed

 

191,976

 

Less: cash acquired

 

776

 

Purchase price, net of cash acquired

$

191,200

 

The purchase price allocation is preliminary as the Company is in the process of collecting additional information. The estimated purchase price allocation previously disclosed in the Form 10-Q for the period ended March 29, 2024 was revised during the second and third quarter of 2024 as new information was received and analyzed resulting in an increase in Inventory of $0.5 million, an increase in Intangible assets of $2.6 million, an increase in Other assets of $0.4 million, an increase in Deferred tax liabilities of $0.6 million, an increase in Other liabilities of $0.7 million and a decrease in Goodwill of $2.2 million.

The fair value of intangible assets for Motion Solutions is comprised of the following:

 

 

 

 

 

 

Estimated Fair

 

 

Amortization

 

Value
(In thousands)

 

 

Period

Developed technologies

$

34,400

 

 

7 years

Customer relationships

 

43,100

 

 

13 years

Backlog

 

5,500

 

 

1 year

Total

$

83,000

 

 

 

The preliminary purchase price allocation resulted in $83.0 million of identifiable intangible assets and $106.6 million of goodwill. As the Motion Solutions acquisition was structured as a stock acquisition for income tax purposes, the goodwill is not

9


NOVANTA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AS OF SEPTEMBER 27, 2024

(Unaudited)

 

deductible. The goodwill recorded represents the anticipated incremental value of future cash flows potentially attributable to: (i) Motion Solution’s ability to grow the business with existing and new customers, including leveraging the Company’s customer base; (ii) Motion Solution’s ability to grow the business through new product introductions; and (iii) cost improvements due to the integration of Motion Solution’s operations into the Company’s existing infrastructure.

The operating results of Motion Solutions were included in the Company’s results of operations beginning January 2, 2024. Motion Solutions contributed revenues of $62.6 million and a loss before income taxes of $1.3 million to the Company’s operating results for the nine months ended September 27, 2024. The loss before income taxes from Motion Solutions for the period from the acquisition date through September 27, 2024 included amortization of inventory fair value adjustments of $2.8 million and amortization of purchased intangible assets of $9.7 million.

Unaudited Pro Forma Information

The pro forma information for all periods presented below includes the effect of business combination accounting resulting from the acquisition of Motion Solutions, including amortization of inventory fair value adjustments, amortization of intangible assets, interest expense on borrowings in connection with the acquisition, and the related tax effects, assuming that the acquisition had been consummated as of January 1, 2023. The pro forma financial information is presented for comparative purposes only and is not necessarily indicative of the results of operations that actually would have been achieved if the acquisition had taken place on January 1, 2023.

 

Three Months Ended

 

 

Nine Months Ended

 

 

September 27,

 

 

September 29,

 

 

September 27,

 

 

September 29,

 

 

2024

 

 

2023

 

 

2024

 

 

2023

 

Revenue

$

244,405

 

 

$

244,686

 

 

$

711,185

 

 

$

734,378

 

Net income

$

19,003

 

 

$

17,159

 

 

$

50,184

 

 

$

45,555

 

Acquisition Costs

Acquisition costs are included in restructuring and acquisition related costs in the consolidated statements of operations. Acquisition-related costs for Motion Solutions was $1.0 million for the nine months ended September 27, 2024.

4. Accumulated Other Comprehensive Loss

Changes in accumulated other comprehensive loss were as follows (in thousands):

 

Total Accumulated

 

 

 

 

 

 

 

 

Other

 

 

Cumulative

 

 

Pension

 

 

Comprehensive

 

 

Translation

 

 

Liability

 

 

Loss

 

 

Adjustments

 

 

Adjustments

 

Balance at December 31, 2023

$

(24,038

)

 

$

(16,604

)

 

$

(7,434

)

Other comprehensive income (loss)

 

10,699

 

 

 

11,053

 

 

 

(354

)

Amounts reclassified from accumulated other comprehensive loss

 

665

 

 

 

 

 

 

665

 

Balance at September 27, 2024

$

(12,674

)

 

$

(5,551

)

 

$

(7,123

)

The amounts reclassified from accumulated other comprehensive loss were included in other income (expense) in the consolidated statements of operations.

5. Earnings per Common Share

Basic earnings per common share is computed by dividing net income by the weighted average number of common shares outstanding during the period. Fully vested restricted stock units and deferred stock units granted to members of the Company’s Board of Directors are included in the calculation of weighted average number of common shares outstanding.

10


NOVANTA INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AS OF SEPTEMBER 27, 2024

(Unaudited)

 

For diluted earnings per common share, the denominator includes the dilutive effect of outstanding common share equivalents. The dilutive effects of outstanding common share equivalents, including outstanding service-based restricted stock units, stock options and performance-based restricted stock units, are determined using the treasury stock method. Performance-based restricted stock units are considered contingently issuable shares, the vesting of which may be based on achievement of specified company financial performance metrics (“attainment-based PSUs”), certain market conditions (“market-based PSUs”) or a hybrid of company financial performance metrics and market conditions (“hybrid PSUs”). The dilutive effects of market-based PSUs are included in the weighted average common share calculation based on the number of shares, if any, that would be issuable as of the end of the reporting period, assuming the end of the reporting period is also the end of the performance period. The dilutive effects of attainment-based and hybrid PSUs are included in the weighted average common share calculation based on the cumulative achievement against the performance targets only when the performance targets have been achieved as of the end of the reporting period.

The following table sets forth the computation of basic and diluted earnings per common share (amounts in thousands, except per share data):

 

Three Months Ended

 

 

Nine Months Ended

 

 

September 27,

 

 

September 29,

 

 

September 27,

 

 

September 29,

 

 

2024

 

 

2023

 

 

2024

 

 

2023

 

Numerators: